On our screens:Cheap stocks by free cash flow yield
Is the price fair?
What CNMD's price assumes
CONMED Corporation trades at 30.9× earnings against 30.9× for the median Medical Devices name, cheaper than its own group.
30.9
Trailing P/E · Medical Devices median 30.9 · cheaper than the typical name in its group
- Price / sales
- 1.08
Price / sales · as of 2025-Q3
- Free cash flow yield
- 14%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- −8.8%
Growth the price implies · The price pays for −8.8% free cash flow growth a year for a decade; the business has delivered +135% a year over the last three.
Details›
- Price / book2025-Q3
- 1.45
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $151M
- Market capitalisation
- $1.04B
- 3-year revenue growth
- +9.6%
- 3-year free cash flow growth
- +135%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 20.1× today against a 44.0× median |
| 52-week range | $32.11 – $55.60 |
| Today | $46.62 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.